Roche submits application in EU for subcutaneous rituximab

Halozyme Therapeutics Inc. (NASDAQ:HALO) said Roche (SIX:ROG; OTCQX:RHHBY) submitted a regulatory application to EMA for a subcutaneous formulation of MabThera rituximab. The submission triggered a $4 million milestone payment to Halozyme from Roche. The product is formulated using Halozyme's Enhanze recombinant human hyaluronidase ( rHuPH20) drug delivery technology. On Monday, Halozyme was up $0.20 to $5.94. ...